TGFβ inhibits IL-1 -induced iNOS expression and NO production in immortalized chondrocytes

Inflammation Research

Volumn 54, Issue 10, 2005, Pages 420-427

  Vuolteenaho, K ^a   Moilanen, T ^a,b   Jalonen, U ^a   Lahti, A ^a   Nieminen, R ^a   Van Beuningen, H M ^c   Van Der Kraan, P M ^c   Moilanen, E ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b Coxa Hospital for Joint Replacement ^*  (Finland)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cartilage; Chondrocytes; Nitric oxide; Osteoarthritis; Transforming growth factor beta

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; MESSENGER RNA; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL IMMORTALIZATION; CONTROLLED STUDY; GENE EXPRESSION; INCUBATION TIME; MOUSE; NONHUMAN; OSTEOARTHRITIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CHONDROCYTES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTERLEUKIN-1; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 27744598749     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-005-1373-6     Document Type: Article

References (48)

1. Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2000; 2: 459-65.
2. Stadler J, Stefanovic-Racic M, Billiar TR, Curran RD, McIntyre LA, Georgescu HI et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991; 147: 3915-20.
3. Charles IG, Palmer RM, Hickery MS, Bayliss MT, Chubb AP, Hall VS et al. Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci USA 1993; 90: 11419-23.
4. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992; 51: 1219-22.
5. Melchiorri C, Meliconi R, Frizziero L, Silvestri T, Pulsatelli L, Mazzetti I et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998; 41: 2165-74.
6. Vuolteenaho K, Moilanen T, al-Saffar N, Knowles RG, Moilanen E. Regulation of the nitric oxide production resulting from the glucocorticoid-insensitive expression of iNOS in human osteoarthritic cartilage. Osteoarthritis Cartilage 2001; 9: 597-605.
7. Häuselmann HJ, Oppliger L, Michel BA, Stefanovic-Racic M, Evans CH. Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in alginate culture. FEBS Lett 1994; 352: 361-4.
8. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994; 200: 142-8.
9. Järvinen TA, Moilanen T, Järvinen TL, Moilanen E. Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage. Mediators Inflamm 1995; 4: 107-11.
10. Cao M, Westerhausen-Larson A, Niyibizi C, Kavalkovich K, Georgescu HI, Rizzo CF et al. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J 1997; 324: 305-10.
11. Hashimoto S, Setareh M, Ochs RL, Lotz M. Fas/Fas ligand expression and induction of apoptosis in chondrocytes. Arthritis Rheum 1997; 40: 1749-55.
12. Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995; 206: 15-21.
13. Studer RK, Georgescu HI, Miller LA, Evans CH. Inhibition of transforming growth factor beta production by nitric oxide-treated chondrocytes: implications for matrix synthesis. Arthritis Rheum 1999; 42: 248-57.
14. Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage 1996; 4: 77-84.
15. Vuolteenaho K, Moilanen T, Hämäläinen M, Moilanen E. Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage. Role of endogenous IL-1 inhibitors. Scand J Rheumatol 2003; 32: 19-24.
16. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996; 184: 1519-24.
17. Ialenti A, Moncada S, Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 1993; 110: 701-6.
18. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993; 178: 749-54.
19. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans C. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 1994; 37: 1062-9.
20. Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994; 179: 651-60.
21. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995; 273: 15-24.
22. de Mello SB, Novaes GS, Laurindo IM, Muscara MN, Maciel FM, Cossermelli W. Nitric oxide synthase inhibitor influences prostaglandin and interleukin-1 production in experimental arthritic joints. Inflamm Res 1997; 46: 72-7.
23. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, Di Paola R et al. Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol 2002; 453: 119-29.
24. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998; 41: 1275-86.
25. Pelletier JP, Jovanovic DV, Lascau-Coman V, Fernandes JC, Manning PT, Connor JR et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000; 43: 1290-9.
26. Grimaud E, Heymann D, Redini F. Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Cytokine Growth Factor Rev 2002; 13: 241-57.
27. van Beuningen HM, Stoop R, Buma P, Takahashi N, van der Kraan PM, van den Berg WB. Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage. Osteoarthritis Cartilage 2002; 10: 977-86.
28. 15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-8.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
30. Lahti A, Jalonen U, Kankaanranta H, Moilanen E. c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages. Mol Pharmacol 2003; 64: 308-15.
31. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997; 272: 4959-63.
32. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-84.
33. Scharstuhl A, Diepens R, Lensen J, Vitters E, van Beuningen H, van der Kraan P et al. Adenoviral overexpression of Smad-7 and Smad-6 differentially regulates TGF-beta-mediated chondrocyte proliferation and proteoglycan synthesis. Osteoarthritis Cartilage 2003; 11: 773-82.
34. Takahashi N, Rieneck K, van der Kraan PM, van Beuningen HM, Vitters EL, Bendtzen K et al. Elucidation of IL-1/TGF-β interactions in mouse chondrocyte cell line by genome-wide gene expression. Osteoarthritis Cartilage 2005; 13: 426-38.
35. Fava R, Olsen N, Keski-Oja J, Moses H, Pincus T. Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med 1989; 169: 291-6.
36. Schlaak JF, Pfers I, Meyer ZBK, Marker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 1996; 14: 155-62.
37. Moos V, Fickert S, Muller B, Weber U, Sieper J. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 1999; 26: 870-9.
38. Ayache N, Boumediene K, Mathy-Hartert M, Reginster JY, Henrotin Y, Pujol JP. Expression of TGF-betas and their receptors is differentially modulated by reactive oxygen species and nitric oxide in human articular chondrocytes. Osteoarthritis Cartilage 2002; 10: 344-52.
39. Vodovotz Y. Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease. Nitric Oxide 1997; 1: 3-17.
40. Amin AR, Di Cesare PE, Vyas P, Attur M, Tzeng E, Billiar TR et al. The expression and regulation of nitric oxide synthase in human osteoarthritis- affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase. J Exp Med 1995; 182: 2097-102.
41. Blanco FJ, Geng Y, Lotz M. Differentiation-dependent effects of IL-1 and TGF-beta on human articular chondrocyte proliferation are related to inducible nitric oxide synthase expression. J Immunol 1995; 154: 4018-26.
42. Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med 1993; 178: 605-13.
43. Hershko A, Ciechanover A. The ubiquitin system. Annual Review of Biochemistry 1998; 67: 425-79.
44. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, Quest AF. Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci USA 2000; 97: 14334-9.
45. Musial A, Eissa NT. Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway. J Biol Chem 2001; 276: 24268-73.
46. Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev 2000; 11: 5-13.
47. Zhang F, Laiho M. On and off: proteasome and TGF-beta signaling. Exp Cell Res 2003; 291: 275-81.
48. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.